Document -
Preclinical study supports a therapeutic role for the immunovascular antibody PC-mAb to preserve cardiac function following heart attack
Scientists report a study of the effect on cardiac remodeling and function following treatment with the fully human antibody PC-mAb from Athera. PC-mAb is designed to alleviate the immune response to vascular inflammation challenges. This preclinical study supports that PC-mAb may have a therapeutic role to reduce the risk for heart failure complications in myocardial infarction patients.
-
License:
Media Use
The content may be downloaded by journalists, bloggers, columnists, creators of public opinion, etc. It can be used and shared in different media channels to convey, narrate, and comment on your press releases, posts, or information, provided that the content is unmodified. The author or creator shall be attributed to the extent and in the manner required by good practice (this means, for example, that photographers should be attributed).
- File format: .pdf